FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379285557> ?p ?o ?g. }

• W4379285557 endingPage "1025" @default.
• W4379285557 startingPage "1025" @default.
• W4379285557 abstract "1025 Background: Radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA) prolongs survival of patients (pts) with prostate cancer. Preliminary immunohistochemistry (IHC)-based studies suggest that PSMA is highly expressed in triple negative breast cancer (TNBC). The PRISMA study aims to assess PSMA expression in pts with metastatic TNBC (mTNBC) via positron-emission tomography/computed tomography (PET/CT) to evaluate the feasibility of PSMA-targeted RLT for TNBC. Methods: PRISMA is a prospective, single-center study that enrolled pts with progressive mTNBC and measurable disease on 18 F-FDG PET/CT to undergo 68 Ga-PSMA-11 PET/CT. TNBC definition (ASCO/CAP) was based on the IHC of the primary breast cancer (BC) or metastasis. Target lesions (TL) were defined as metastatic lesions ≥1.5 cm with significant uptake in 18 FDG-PET/CT. The same TL regions were propagated to the 68 Ga-PSMA-PET/CT. 68 Ga-PSMA-11 maximum standard uptake value (SUV max ) was measured for each TL. PSMA patterns A and B were defined according to presence of a majority (pattern A) or a minority (pattern B) of positive TL on 68 Ga-PSMA (ie. uptake greater than that of normal liver parenchyma). Mann-Whitney U test was used to assess differences in median SUV max (mSUV max ) between subgroups. Results: Ten pts with progressive mTNBC were enrolled. One pt was excluded due to lack of TL on 18 FDG-PET/CT. Median age was 48 years (range 36-68), median number of TL per patient was 8 (5-18). Five pts had a TNBC IHC since the initial BC diagnosis, while 4 had a switch to TNBC (4 with initial estrogen receptor [ER]-positive and 1 with HER2-positive BC). All evaluable pts had inter- and intra-organ heterogeneity in PSMA uptake in TL and 2 pts had some mismatch with FDG-positive and PSMA-negative TL. mSUV max was 2.99 (range 1.7-6.3) in the overall population and was higher in pts with pattern A (5.1 vs 2.6 in patterns A and B, respectively, p = 0.03). mSUVmax was numerically higher in younger pts (5.0 vs 2.6 in pts <50y and ≥50y, p = 0.28), PD-L1-positive (5.0 vs 2.7 in PD-L1-positive and -negative, p = 0.14), de novo metastatic disease (5.0 vs 2.9 in de novo and recurrent BC, p = 0.38) and those with ER-negative primary breast tumor (3.4 vs 3.0 in ER-negative and ER-positive primary BC, p = 0.9). Conclusions: A significant PSMA uptake was observed in a proportion of pts with mTNBC. Inclusion of additional pts and translational analyses will allow the identification of PSMA expression determinants. PSMA-targeted RLT may be considered as an innovative therapeutic strategy to be explored in selected pts with mTNBC. [Table: see text]" @default.
• W4379285557 created "2023-06-05" @default.
• W4379285557 creator A5019615152 @default.
• W4379285557 creator A5034961078 @default.
• W4379285557 creator A5067552665 @default.
• W4379285557 creator A5071051371 @default.
• W4379285557 creator A5076399682 @default.
• W4379285557 creator A5078388793 @default.
• W4379285557 creator A5084918821 @default.
• W4379285557 creator A5092084558 @default.
• W4379285557 date "2023-06-01" @default.
• W4379285557 modified "2023-09-25" @default.
• W4379285557 title "Prostate-specific membrane antigen (PSMA) expression in patients with metastatic triple negative breast cancer: Initial results of the PRISMA study." @default.
• W4379285557 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.1025" @default.
• W4379285557 hasPublicationYear "2023" @default.
• W4379285557 type Work @default.
• W4379285557 citedByCount "0" @default.
• W4379285557 crossrefType "journal-article" @default.
• W4379285557 hasAuthorship W4379285557A5019615152 @default.
• W4379285557 hasAuthorship W4379285557A5034961078 @default.
• W4379285557 hasAuthorship W4379285557A5067552665 @default.
• W4379285557 hasAuthorship W4379285557A5071051371 @default.
• W4379285557 hasAuthorship W4379285557A5076399682 @default.
• W4379285557 hasAuthorship W4379285557A5078388793 @default.
• W4379285557 hasAuthorship W4379285557A5084918821 @default.
• W4379285557 hasAuthorship W4379285557A5092084558 @default.
• W4379285557 hasConcept C121608353 @default.
• W4379285557 hasConcept C126322002 @default.
• W4379285557 hasConcept C143998085 @default.
• W4379285557 hasConcept C199374082 @default.
• W4379285557 hasConcept C20417620 @default.
• W4379285557 hasConcept C204232928 @default.
• W4379285557 hasConcept C2775842073 @default.
• W4379285557 hasConcept C2775930923 @default.
• W4379285557 hasConcept C2780110267 @default.
• W4379285557 hasConcept C2780192828 @default.
• W4379285557 hasConcept C2989005 @default.
• W4379285557 hasConcept C530470458 @default.
• W4379285557 hasConcept C71924100 @default.
• W4379285557 hasConceptScore W4379285557C121608353 @default.
• W4379285557 hasConceptScore W4379285557C126322002 @default.
• W4379285557 hasConceptScore W4379285557C143998085 @default.
• W4379285557 hasConceptScore W4379285557C199374082 @default.
• W4379285557 hasConceptScore W4379285557C20417620 @default.
• W4379285557 hasConceptScore W4379285557C204232928 @default.
• W4379285557 hasConceptScore W4379285557C2775842073 @default.
• W4379285557 hasConceptScore W4379285557C2775930923 @default.
• W4379285557 hasConceptScore W4379285557C2780110267 @default.
• W4379285557 hasConceptScore W4379285557C2780192828 @default.
• W4379285557 hasConceptScore W4379285557C2989005 @default.
• W4379285557 hasConceptScore W4379285557C530470458 @default.
• W4379285557 hasConceptScore W4379285557C71924100 @default.
• W4379285557 hasIssue "16_suppl" @default.
• W4379285557 hasLocation W43792855571 @default.
• W4379285557 hasOpenAccess W4379285557 @default.
• W4379285557 hasPrimaryLocation W43792855571 @default.
• W4379285557 hasRelatedWork W2080006760 @default.
• W4379285557 hasRelatedWork W2317787856 @default.
• W4379285557 hasRelatedWork W2619811894 @default.
• W4379285557 hasRelatedWork W2894547582 @default.
• W4379285557 hasRelatedWork W3093499920 @default.
• W4379285557 hasRelatedWork W3136253156 @default.
• W4379285557 hasRelatedWork W3165855941 @default.
• W4379285557 hasRelatedWork W4229050537 @default.
• W4379285557 hasRelatedWork W4280499769 @default.
• W4379285557 hasRelatedWork W4293020281 @default.
• W4379285557 hasVolume "41" @default.
• W4379285557 isParatext "false" @default.
• W4379285557 isRetracted "false" @default.
• W4379285557 workType "article" @default.